Quick Take
Nkarta (NKTX) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement.
The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications.
NKTX is still at preclinical stage of development for its pipeline, so the IPO is likely more relevant to institutional investors with a long-term hold time frame.
Company & Technology
South San Francisco, California-based Nkarta was founded to engineer what it calls natural killer [NK] cell therapies to treat blood and other